REAH GAMBRELL: Open Payments
NPI 1144830597 · WICHITA FALLS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,743 in 164 payments from 17 companies in 2025. Trend: 2023 $2,083 · 2024 $1,787 · 2025 $3,743
Food & beverage: $3,673Education: $70
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 30 | $652 |
| Neurocrine BioSciences, Inc. | 18 | $621 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $392 |
| E.R. Squibb & Sons, L.L.C. | 10 | $291 |
| Alkermes, Inc. | 14 | $239 |
| Corium, LLC | 11 | $226 |
| Collegium Pharmaceutical, Inc. | 12 | $210 |
| Vanda Pharmaceuticals Inc. | 7 | $166 |
| Lundbeck LLC | 10 | $156 |
| ABBVIE INC. | 8 | $154 |
Products named: REXULTI, INGREZZA, CAPLYTA, COBENFY, ARISTADA, Azstarys, Jornay PM, FANAPT.
Industry payments across TX — which companies pay providers there.
